Abstract
Vulvar cancer is a rare gynecological malignancy. However, the incidence of human papilloma virus (HPV)-associated vulvar disease is increasing, particularly in low- and middle- income countries. Human immunodeficiency virus (HIV) infection is also associated with an increased risk of vulvar cancer. Patterns of care for vulvar cancer in low resource-limited settings with high rates of HPV and HIV co-infection have not been well described. Women with vulvar cancer who presented to an oncology clinic in Botswana from January 2015 through October 2019 were prospectively enrolled in this observational cohort study. Factors associated with survival including age, HIV status, stage, and treatment were evaluated. Analysis of 128 women with vulvar cancer demonstrated a median age of 42 years. At presentation 53.3% of patients were early stage (stage I/II) and 46.6% were late stage (stage III/IV). The majority of patients were living with well-controlled HIV infection (89%, n = 107) with a median CD4 count of 461 cell/ul (IQR 300.5-684.5) and high level of viral suppression (95% with viral copies & <400). Surgery was performed in 25 (20.8%) patients, 29 (24%) patients received chemotherapy, and 81 (67.5%) received radiation therapy. Adjusted analysis controlling for HIV, age, stage, surgery, chemotherapy and radiation demonstrated no differences in survival at 32 months by HIV status (HR, 0.426; 95% CI, 0.112-1.5976). Advanced stage (stage III and IV) (HR, 2.41; (95% CI, 1.03-5.68) and older age (HR, 1.05; (95% CI, 1.00-1.10) were associated with worse survival while receipt of surgery was associated with improved survival (HR 0.09, 95% CI 0.15-0.74). Women in Botswana with vulvar cancer have a high rate of HIV infection. They present at a young age and just under half of patients present at a late stage. While decreased survival was associated with older age and late stage disease, HIV status did not impact survival outcomes. Efforts to identify patients early with limited disease burden may be necessary to improve outcomes in the future.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.